Clinical Report: Immunothrombosis in Tuberculosis Pathogenesis and Immune Response

Overview

Immunothrombosis plays a critical role in the immune response to Mycobacterium tuberculosis by forming microthrombi that trap the pathogen and prevent dissemination. Dysregulated immunothrombosis may contribute to tuberculosis pathogenesis, including drug resistance, lung damage, and increased risk of venous thromboembolism.

Background

Tuberculosis (TB) remains a leading infectious cause of death worldwide, complicated by multidrug resistance and chronic lung disease even after treatment. Immunothrombosis, a process involving coagulation activation by immune cells to contain pathogens, has been implicated in other infections but is newly recognized in TB. Understanding the role of immunothrombosis in TB could reveal novel host-directed therapies to reduce tissue damage and improve outcomes. The COVID-19 pandemic highlighted the importance of thromboinflammatory processes, providing insights applicable to TB immunopathogenesis.

Data Highlights

Key epidemiological and laboratory findings include:

• Estimated 400,000 multidrug-resistant TB cases in 2023 globally.
• Reported pulmonary embolism prevalence in TB patients varies from 0.6% to over 5%, with higher rates in HIV co-infection and severe illness.
• Elevated coagulation markers in TB patients: D-dimer, fibrinogen, and von Willebrand factor (vWF).
• Upregulation of tissue factor (TF) in Mtb-infected macrophages compared to controls.
• Mouse models show increased Mtb growth with myeloid TF deficiency and impaired granuloma formation with low TF expression.
• Proteomic and transcriptomic studies reveal enrichment of coagulation and endothelial dysfunction pathways in TB lung tissue, especially in multidrug-resistant cases and fibrotic lesions.

Key Findings

• Immunothrombosis involves macrophages, neutrophils, and platelets forming microthrombi to contain Mtb at infection sites.
• Dysregulated immunothrombosis may promote drug resistance by impairing drug delivery and contribute to lung tissue damage and venous thromboembolism.
• Coagulation activation markers such as D-dimer, fibrinogen, and vWF are elevated in TB, indicating endothelial dysfunction and thromboinflammation.
• Tissue factor expression by macrophages is upregulated in response to Mtb and is essential for granuloma formation and controlling bacterial growth.
• Neutrophil extracellular traps (NETs) contribute to immunothrombosis by trapping Mtb and promoting coagulation.
• Transcriptomic analyses show persistent endothelial dysfunction and thromboinflammatory signaling in TB lesions, correlating with fibrosis and post-TB lung disease.

Clinical Implications

Recognition of immunothrombosis as a key mechanism in TB pathogenesis suggests that targeting coagulation pathways and endothelial dysfunction could be a novel approach for host-directed therapies. Monitoring coagulation markers may help identify patients at risk of thrombotic complications and lung damage. Therapeutic modulation of immunothrombosis might improve drug delivery, reduce tissue destruction, and mitigate the development of drug resistance.

Conclusion

Immunothrombosis is a pivotal component of the immune response to Mtb, with both protective and pathogenic roles. Further research into its mechanisms may enable development of targeted therapies to reduce TB morbidity and improve treatment outcomes.

References

1. World Health Organization 2023 -- Global Tuberculosis Report
2. Studies on coagulation markers and endothelial dysfunction in TB
3. Research on tissue factor and granuloma formation in TB
4. Proteomic and transcriptomic analyses of TB lung tissue